InMed gets Nasdaq notice after stockholders’ equity falls below $2.5 million minimum

InMed received a Nasdaq notice for failing the $2.5 million minimum stockholders’ equity requirement in its fiscal 2026 Form 10-K. Stockholders’ equity was $1,075,007, putting the company at risk of delisting from the Nasdaq Capital Market. Nasdaq gave 45 days to submit a compliance plan; an accepted plan could secure up to a 180-day extension. Management expects the Mentari merger and related pre-closing financing to restore compliance, with about $490 million in gross proceeds anticipated. If compliance is not regained, Nasdaq could move to delist; an appeal would keep shares trading pending a hearings process. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-101492), on September 18,